MedTrace Logo

Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

NCT04141020 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-03-23

No results posted yet for this study

Summary

The objective of this study is to explore the effects of Sirolimus on the underlying molecular alterations of cerebral aneurysms.

Conditions

  • Cerebral Aneurysm

Interventions

PROCEDURE

Microsurgical clipping

Standard of care microsurgical clipping of an unruptured cerebral artery aneurysm.

PROCEDURE

Endovascular treatment

Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.

DRUG

Sirolimus

Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • University of Miami

    lead OTHER

Principal Investigators

  • Robert M Starke, M.D. · University of Miami

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-27
Primary Completion
2026-11-01
Completion
2026-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04141020 on ClinicalTrials.gov